The Asia Pacific medical foods market size was valued at USD 6.1 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 6.3% from 2023 to 2030. The Asia Pacific (APAC) market is fairly untapped and rapid urbanization and development in the region have widened the medical foods industry. The growing geriatric population and diseases associated with old age are key factors contributing to the growth. Lifestyle diseases associated with a sedentary lifestyle that comes with modernization and urbanization are on the rise in the region. Awareness about leading a healthy lifestyle is a key factor for the increased adoption of medical foods as preventative measures to reduce symptoms of diseases and certain diseases altogether.
According to the United Nations Population Fund (UNFPA), by 2050 Asia Pacific will have one in four people aged above 60. The geriatric population will be nearly 1.3 billion. With the increase in the geriatric population, health issues arising due to the same have also been on the rise. Lifestyle diseases associated with aging are also key factors contributing to the growth of the market.
Asia Pacific region where urbanization and development have increased the overall life expectancy but have also caused a shift in causes of mortality from communicable diseases to non-communicable diseases. The leading factor for mortality is cardiovascular diseases and cancer. According to the OECD data, cancer caused nearly 4.5 million deaths in the APAC region.
The increase in overall awareness around medical food has driven the market growth significantly in recent years. The markets in China and South Korea are seeing massive uptake of medical foods and the demand for the same is steadily rising. In lieu of this, the countries are speeding up processes for more imports and also investing in their portfolios to expand in the regional market. The market for medical foods pertaining to specific rare diseases is gaining momentum and being prioritized for registration by the governments.
Pandemic Impact |
Post-COVID Outlook |
The Asia Pacific medical foods expanded by 10.4% from 2019 to 2020. |
The market is expected to expand at a CAGR of 6.4% from 2022 to 2030. |
With the onset of the pandemic, the logistics of the medical food market were affected negatively, in the APAC region which primarily imports medical foods, the revenue earnings were severely impacted. |
COVID-19 brought awareness regarding immunity and overall health, which the population across APAC acknowledged. The demand for medical food has grown multifold and will continue to rise. |
Nestlé Health Science China has launched two products for infants in the region which obtained FSMP status. |
Better regulatory framework and prioritization of medical foods related to rare diseases are driving the market growth in the APAC region. Companies are focusing on building robust portfolios for medical foods to access the untapped potential of the market. |
The COVID-19 pandemic restrained the growth and development of the Asia Pacific medical foods market. The rapid urbanization and high burden of the diseases coupled with the massive impact that the pandemic had on the health of people have increased the uptake of medical foods. This in turn has resulted in the growth of the industry.
The oral route of administration segment held a staggering market share of 68.8% in the region. The growth can be attributed to the wider product range in this segment. Major players in the medical food industry have product portfolios catering to the demand for the oral route of administration, which is a key factor driving this market. The oral route has been the most preferred format for the administration of medical foods, due to its ease and wider acceptance.
The enteral feeding segment, on the other hand, is expected to witness the fastest CAGR in the forecast period. This growth of the segment can be due to the rise in the geriatric population and diseases afflicting them. Some chronic conditions render the oral route of administration impossible or futile, thus enteral feeding becomes the choice for better nutrition management in patients with special needs.
The powder segment held the largest market share of 35.5% in 2022. Higher product availability and longer shelf-life of this type of product have brought about the growth of this segment. Product portfolios of all the major players in the industry mainly consist of powder formulations and are a key factor for a large revenue share.
The liquid product type is expected to register the fastest CAGR in the forecast period. Expansion of product portfolios by medical food players is a key factor contributing to the rapid growth of this segment. The ease of use of liquid formulations for infants and adults alike is also a key factor contributing to the growth of the segment.
Chemotherapy-induced diarrhea held the largest market share of 15.3% in 2022. As per the data obtained by the WHO, cancer caused nearly 4.5 million deaths in a year in the region. Consumers and patients are becoming more aware of the need to manage disease symptoms and side effects; this has been a key factor driving growth. Clinicians and doctors are more open to non-traditional methods and medically nutritive foods for nutritional supplementation.
Diabetic neuropathy is expected to emerge as the fastest-growing segment over the forecast period. Diabetes, as a lifestyle disease, has seen an overall increase in recent years, especially with the urbanization and fast development in the region, its prevalence has increased. Diabetes and its associated symptoms can be managed with proper nutrition, this is the key factor contributing to the rapid growth of this segment.
The institutional sales channel held the largest revenue share of 41.1% in 2022. The region is untapped in terms of market size as of now and the only preferred way of dispensing medical foods under a doctor’s supervision is through institutional sales, where medical representatives directly provide products to clinicians and doctors at clinics and care centers. Limited awareness of the patients and reluctance of medical practitioners for prescribing medical foods are the key factors for the large revenue share of this segment.
The online sales channel segment is expected to witness the fastest growth in the forecast period. Increasing popularity and acceptance of medical foods, on the whole, are expected to fuel the growth of the segment. The majority of players in the Asia Pacific medical foods market have been growing their distribution channels and expanding their reach by providing products directly to consumers.
China had the largest market share of 20.8% in 2021. The increase in awareness in the Chinese population regarding the health benefits and the use of medical foods in mitigating and managing diseases and their symptoms has grown in recent years. The public has been more welcoming to medical foods for completing nutritional requirements for the elderly and patients with cancer.
India is anticipated to register the fastest CAGR over the forecast period, owing to the rapidly growing population, rising geriatric & infant populations, and increasing disease prevalence. Rising awareness about medical foods and their benefits in managing symptoms of diseases has been the primary factor for the growth of this region.
Key players are still subsidiaries owned by foreign companies; regional companies are also expanding their operations in the Asia Pacific region. China’s firm Feihe’s has been gaining a lot of popularity in the region due to its recent development, the firm has decided to expand its geographical reach and product portfolio. Regional players in India and China have majorly captured the regional market after the foreign companies. Some prominent players in the Asia Pacific medical foods market include:
Mead Johnson
SHS International ltd
Synutra International ltd
Milupa Gmbh
Danone
Nestlé
Abbott
Fresenius Kabi AG
GlaxoSmithKline PLC
Report Attribute |
Details |
The market size value in 2023 |
USD 6.5 billion |
The revenue forecast in 2030 |
USD 9.9 billion |
Growth Rate |
CAGR of 6.3 % from 2023 to 2030 |
The base year for estimation |
2022 |
Historical data |
2018 - 2021 |
Forecast period |
2023 - 2030 |
Quantitative units |
Revenue in USD million, and CAGR from 2023 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Route of administration, product type, application, sales channel, region |
Regional scope |
Asia Pacific |
Country scope |
Japan; China; Australia; New Zealand; India; Singapore; South Korea; Thailand |
Key companies profiled |
Mead Johnson; SHS International ltd; Synutra International ltd; Milupa Gmbh; Danone; Nestlé; Abbott; Fresenius Kabi AG; GlaxoSmithKline PLC |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at the regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2030. For this study, Grand View Research, Inc. has segmented the Asia Pacific medical foods market report based on the route of administration, product type, application, sales channel, and region:
Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
Oral
Enteral
Product Type Outlook (Revenue, USD Million, 2018 - 2030)
Pills
Powders
Others
Application Outlook (Revenue, USD Million 2018 - 2030)
Chronic Kidney Disease
Minimal Hepatic Encephalopathy
Chemotherapy-Induced Diarrhea
Pathogen Related Infections
Diabetic Neuropathy
ADHD
Depression
Alzheimer's Disease
Nutritional Deficiency
Orphan Diseases
Phenylketonuria
Eosinophilic Esophagitis
FPIES
Others
Wound Healing
Chronic Diarrhea
Constipation Relief
Protein Booster
Dysphagia
Other Diseases
Parkinson’s Disease
Epilepsy
Pain Management
Other Cancer Related Treatments
Sales Channel Outlook (Revenue, USD Million, 2018 - 2030)
Online Sales
Retail Sales
Institutional Sales
Country Outlook (Revenue, USD Million, 2018 - 2030)
Japan
China
India
Australia
New Zealand
Singapore
South Korea
Thailand
b. The Asia Pacific medical foods market size was estimated at USD 5.7 billion in 2021 and is expected to reach USD 6.1 billion in 2022.
b. The Asia Pacific medical foods market is expected to grow at a compound annual growth rate of 6.4% from 2022 to 2030 to reach USD 9.9 billion by 2030.
b. China dominated the Asia Pacific medical foods market with a share of 20.8% in 2021. The increase in awareness in the Chinese population towards health benefits and use of medical foods in mitigating and managing diseases and their symptoms has grown in recent years.
b. Some key players operating in the Asia Pacific medical foods market include Mead Johnson; SHS International ltd; Synutra International ltd; Milupa Gmbh; Danone; Nestlé; Abbott; Fresenius Kabi AG; GlaxoSmithKline PLC
b. The Asia Pacific (APAC) medical foods market is fairly untapped and rapid urbanization and development in the APAC region has widened the medical foods industry. Growing geriatric population and diseases associated with old age are key factors contributing to its growth.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
We value your investment and offer free customization with every report to fulfil your exact research needs.